Suboxone is the brand name for a fixed-dose combination of buprenorphine and naloxone, FDA-approved for the treatment of opioid use disorder (OUD). Buprenorphine is a partial mu-opioid agonist. it binds to the same opioid receptors as heroin, oxycodone, and fentanyl, but produces a ceiling effect that limits the euphoria and respiratory depression associated with full agonists.
Naloxone is included as an abuse deterrent. When taken sublingually as directed, naloxone has minimal bioavailability and does not significantly oppose the buprenorphine effect. If the film or tablet is dissolved and injected, naloxone becomes active, precipitates withdrawal, and discourages intravenous misuse.
Suboxone is dosed once or twice daily and is highly effective at retaining patients in treatment, reducing illicit opioid use, and lowering overdose mortality during the maintenance phase. It is a legitimate, evidence-based intervention. particularly in harm reduction contexts. However, it does not resolve physical opioid dependence. Patients who discontinue Suboxone experience a buprenorphine withdrawal syndrome that can be prolonged and severe, owing to buprenorphine's long half-life of 24 to 60 hours and exceptionally high receptor affinity. Many patients who contact MindScape Retreat have found Suboxone helpful in stabilizing their lives, but are now seeking a path beyond indefinite maintenance.
Suboxone Clinical Profile
Ibogaine Clinical Profile
Ibogaine is a naturally occurring indole alkaloid extracted from the root bark of the Central African shrub Tabernanthe iboga. Used ceremonially by the Bwiti people of Gabon for centuries, ibogaine has emerged over the past three decades as one of the most pharmacologically distinctive anti-addiction compounds known to medicine.
Unlike Suboxone, which occupies opioid receptors daily to manage withdrawal, ibogaine acts as a multi-receptor modulator, engaging opioid receptors, NMDA receptors, serotonin transporters, sigma-2 receptors, and nicotinic acetylcholine receptors simultaneously. This broad receptor engagement produces an acute neurochemical reset that eliminates the physical symptoms of opioid withdrawal within hours of a single administration.
Beyond withdrawal interruption, ibogaine triggers upregulation of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF). These proteins promote synaptic remodeling, receptor normalization, and the restoration of dopaminergic signaling pathways damaged by chronic opioid use, neurobiological changes that appear to underlie the durable reductions in craving and substance use reported in observational clinical studies.
At MindScape Retreat in Cozumel, Mexico, ibogaine is administered in a single medically supervised session under the clinical direction of Dr. Omar Calderon, M.D., with continuous cardiac monitoring, IV access, and a full medical care team present throughout the 24 to 36 hour treatment window.
A structured comparison across mechanism, dependency risk, withdrawal management, neuroplasticity, psychological component, and long-term cost.
| Factor | Ibogaine (MindScape Retreat) | Suboxone (Buprenorphine/Naloxone) |
|---|---|---|
| Mechanism | Multi-receptor reset, opioid, NMDA, serotonin, sigma-2; promotes BDNF/GDNF neuroplasticity cascade | Partial mu-opioid agonist (buprenorphine) + abuse-deterrent antagonist (naloxone), suppresses withdrawal while maintaining partial receptor activation daily |
| Treatment Duration | Single 24 to 36 hour medically supervised session + integration support | Daily sublingual dosing. often months to years, frequently indefinite maintenance |
| Withdrawal Management | Eliminates acute opioid withdrawal symptoms within hours by resetting receptor function neurologically | Suppresses withdrawal while dose is maintained; cessation triggers buprenorphine withdrawal syndrome |
| Dependency Risk | Non-habit-forming. Ibogaine does not create physical opioid receptor dependence | Creates buprenorphine physical dependence. Stopping Suboxone triggers protracted withdrawal lasting weeks |
| Neuroplasticity | Upregulates BDNF and GDNF; promotes synaptic remodeling and long-term receptor normalization | No documented neuroplastic effects; receptor engagement continues passively while medicated |
| Psychological Component | Visionary introspective experience promotes trauma processing, insight, and root-cause psychological resolution | No psychoactive psychological component; behavioral therapy is a separate, adjunct requirement |
| Medical Supervision | Intensive pre-screening (EKG, labs, cardiac clearance), continuous cardiac monitoring during full session | Regular prescribing physician oversight and check-ins; less intensive than ibogaine session monitoring |
| Success Metrics | 60 to 80% report significant reduction in opioid use at 12 months in published observational studies | 40 to 60% remain abstinent from illicit opioids while actively maintained; high relapse on cessation |
| Cost Structure | Single upfront investment ($6,000 to $12,000 at MindScape); no ongoing pharmaceutical cost | Lower per-visit cost but ongoing, $1,500 to $6,000+ annually including monitoring and dispensing fees |
| FDA Status | Not FDA-approved; legally administered at licensed medical clinics in Mexico under physician supervision | FDA-approved for opioid use disorder (OUD). Schedule III controlled substance since 2002 |
Highlighted rows indicate areas where ibogaine demonstrates a distinct clinical advantage. Individual outcomes vary. This information is educational and does not constitute medical advice. Consult a qualified clinician before making treatment decisions.
Suboxone substitutes one opioid dependency for another. Patients who stop Suboxone experience buprenorphine withdrawal, sometimes lasting 6 to 8 weeks, because their opioid receptors remain dependent on daily partial agonist activation. Ibogaine does not create physical dependency. After a single session, patients are neurochemically free from opioid receptor dependence without substituting a new maintenance pharmaceutical.
Suboxone is pharmacologically passive from a neuroplastic standpoint. it occupies receptors and prevents withdrawal while you take it, but does not restructure the underlying neural architecture of addiction. Ibogaine actively promotes neuroplasticity through BDNF and GDNF upregulation, driving synaptic remodeling and restoration of the dopaminergic reward pathways chronically dysregulated by opioid use.
One of ibogaine's most clinically significant properties is its visionary, introspective component. Under medical supervision at MindScape, patients typically experience a profound inward journey that facilitates processing of underlying trauma, adverse childhood experiences, and the psychological roots of addictive behavior. This dimension is entirely absent from Suboxone maintenance and is considered integral to ibogaine's long-term recovery outcomes.
Suboxone requires daily adherence indefinitely, missed doses trigger withdrawal within 24 to 48 hours. The logistical, financial, and psychological burden of daily controlled-substance management can itself become a quality-of-life impairment. Ibogaine requires a single medically supervised session. Patients leave MindScape free from daily pharmaceutical dependency, with integration support, not a prescription refill, as their ongoing recovery tool.
Many patients who contact MindScape Retreat have already completed one or more Suboxone maintenance courses. They recognize Suboxone's harm-reduction value, it kept them alive and out of crisis, but are seeking something Suboxone cannot provide: genuine neurochemical freedom from opioid dependence.
The most consistent reasons patients cite for choosing ibogaine over continued Suboxone maintenance include:
For additional clinical context, review our ibogaine case study for Suboxone and methadone patients and our full overview of ibogaine for methadone and Suboxone treatment.
MindScape Patient Outcomes
Figures represent observational patient outcomes from MindScape Retreat clinical records 2019 to 2025. Individual results vary. This information is educational and does not constitute a clinical guarantee.
MindScape Retreat does not advocate against Suboxone. it is a life-saving intervention for many patients. Ibogaine is not appropriate for everyone, and honest clinical guidance means acknowledging that.
Ibogaine prolongs the cardiac QTc interval and is contraindicated in patients with structural heart disease, a history of arrhythmia, Long QT syndrome, or baseline QTc above safe thresholds. These patients should remain on Suboxone or pursue other evidence-based MAT options.
Review full contraindicationsIbogaine treatment is absolutely contraindicated in pregnancy. Buprenorphine (Suboxone) is the recommended standard of care for opioid use disorder during pregnancy. it is substantially safer than untreated opioid dependence and is not associated with major congenital malformations at therapeutic doses.
Ibogaine is not FDA-approved and must be administered at licensed international clinics such as MindScape Retreat in Cozumel, Mexico. Patients who are medically unable to travel or who lack the logistical capacity for international treatment should pursue Suboxone or other FDA-approved MAT through their local provider.
Some patients prefer to remain within the FDA-approved treatment ecosystem, due to insurance coverage requirements, employer drug testing policies, personal beliefs regarding psychedelic treatment, or the guidance of their local physician. Suboxone is a medically validated, guideline-recommended option that is entirely appropriate for these patients.
Active psychosis, untreated bipolar I disorder, and certain severe personality disorders can significantly increase the psychological risk of the ibogaine experience. These patients should undergo thorough psychiatric evaluation before considering ibogaine. Suboxone may be more appropriate while psychiatric stabilization is first established.
While ibogaine's long-term cost profile can compare favorably to years of Suboxone maintenance, the upfront treatment investment presents a barrier for some patients. For those without access to ibogaine treatment funds, Suboxone remains an accessible, effective, and life-saving option available through standard healthcare channels.
Transitioning from Suboxone to ibogaine requires careful, individualized clinical planning. Buprenorphine's exceptionally high mu-opioid receptor affinity, greater than most full agonists and significantly greater than ibogaine itself, means that if ibogaine is administered while buprenorphine is still occupying receptors at therapeutic levels, the treatment will be substantially attenuated and may precipitate acute withdrawal.
Under the clinical direction of Dr. Omar Calderon, M.D., MindScape designs individualized taper and washout protocols for every Suboxone patient, calibrated to their current dose, duration of maintenance, and individual tolerance profile. The general treatment sequence is:
Structured Buprenorphine Taper
We design a taper schedule targeting a low buprenorphine dose of 2 to 4 mg/day, reducing slowly enough to minimize withdrawal discomfort. For patients on high doses (16 to 32 mg), this taper may take 4 to 8 weeks and is conducted with clinical support throughout.
Defined Washout Period
Once at the low-dose threshold, a washout period allows buprenorphine to dissociate sufficiently from opioid receptors. A minimum of 36 to 72 hours is required; longer washout is preferred for optimal ibogaine efficacy. Clinical monitoring continues during this phase.
Comprehensive Pre-Treatment Screening
Full cardiac workup including EKG and echocardiogram if indicated, comprehensive blood labs including liver function, psychological evaluation, and a complete medication interaction review are completed before any ibogaine is administered.
Ibogaine Treatment Session
A single medically supervised 24 to 36 hour session at our Cozumel, Mexico facility. Continuous cardiac monitoring via telemetry, IV access maintained, and our full clinical care team, including Dr. Calderon and nursing staff, present throughout the entire session.
Integration and Aftercare
Post-session integration with our clinical psychologists, a personalized recovery and aftercare plan, and access to our booster protocol for patients who benefit from additional support weeks or months following the initial treatment.
Dr. Omar Calderon, M.D.
Clinical Director, MindScape Retreat. Cozumel, Mexico
“The transition from Suboxone to ibogaine is one of the most clinically nuanced protocols we execute. Buprenorphine's receptor affinity demands patience and precision in the taper. When the washout is executed correctly, ibogaine can provide these patients with something Suboxone never could, genuine neurochemical freedom from opioid dependence, without substituting a new one.”
Every patient transitioning from Suboxone undergoes a comprehensive pre-admission consultation with our clinical team to establish the appropriate taper timeline, confirm cardiac and hepatic eligibility, review all medications for interactions, and ensure a safe and effective treatment sequence.
Schedule a Pre-Screening ConsultationIf you are currently on Suboxone and seeking a path beyond daily maintenance, MindScape Retreat's clinical team in Cozumel, Mexico can determine whether you are a candidate for ibogaine treatment. All consultations begin with a confidential pre-screening with Dr. Omar Calderon's team. no commitment required.
MindScape Retreat has treated 900+ patients since 2019 under full medical supervision in Cozumel, Mexico. All treatments are conducted under the direction of Dr. Omar Calderon, M.D. This page is for informational purposes only and does not constitute medical advice. Individual results vary.